Clinical Trials Logo

Clinical Trial Summary

This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study evaluating the investigational multivalent group B streptococcus vaccine. Healthy adults aged 18 to 49 years of age with no history of group B streptococcal vaccination will be randomized to receive either a single intramuscular dose of multivalent group B streptococcus vaccine (various formulations at 3 dose levels) or a placebo (saline control).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03170609
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date June 5, 2017
Completion date June 25, 2018

See also
  Status Clinical Trial Phase
Completed NCT05782179 - Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants Phase 1
Completed NCT04258995 - A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS Phase 2
Recruiting NCT05726006 - Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults.